Provided by Tiger Fintech (Singapore) Pte. Ltd.

Glaukos

88.30
-1.9600-2.17%
Pre-market: 89.200.9000+1.02%06:18 EDT
Volume:772.04K
Turnover:67.97M
Market Cap:4.99B
PE:-31.82
High:89.86
Open:88.94
Low:87.17
Close:90.26
Loading ...

Glaukos's Corneal Disease Drug Accepted for FDA Review

MT Newswires Live
·
24 Feb

Glaukos Corp - Pdufa Date for Epioxa Nda Set for October 20, 2025

THOMSON REUTERS
·
24 Feb

Glaukos Announces FDA Acceptance of Nda Submission for Epioxa™

THOMSON REUTERS
·
24 Feb

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Business Wire
·
24 Feb

We're Not Worried About Glaukos' (NYSE:GKOS) Cash Burn

Simply Wall St.
·
23 Feb

Glaukos Corp. Reports Record Sales in Earnings Call

TIPRANKS
·
22 Feb

Glaukos Down Over 18%, on Pace for Largest Percent Decrease Since July 2021 -- Data Talk

Dow Jones
·
22 Feb

BUZZ-U.S. STOCKS ON THE MOVE-MercadoLibre, CrowdStrike Holdings, Protagonist Therapeutics

Reuters
·
22 Feb

Glaukos price target raised to $176 from $149 at Needham

TIPRANKS
·
22 Feb

Stock Track | Glaukos (GKOS) Plummets 13.2% as Wider Q4 Loss Disappoints Investors

Stock Track
·
21 Feb

Stock Track | Glaukos Plunges 11.67% in Pre-market on Wider Q4 Loss

Stock Track
·
21 Feb

BUZZ-Glaukos falls on wider-than-expected Q4 loss

Reuters
·
21 Feb

GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline

Zacks
·
21 Feb

Glaukos Is Maintained at Buy by Needham

Dow Jones
·
21 Feb

S&P 500 Futures Steady In Premarket Trading; Celsius Holdings, MercadoLibre Lead

Dow Jones
·
21 Feb

Glaukos Corp. : Wells Fargo Raises Target Price to $160 From $153

THOMSON REUTERS
·
21 Feb

Analysts Conflicted on These Healthcare Names: Glaukos (GKOS), Danaher (DHR) and Evolent Health (EVH)

TIPRANKS
·
21 Feb

Glaukos: Surpassing Milestones with Robust Growth in Glaucoma Segment and Promising iDose Integration

TIPRANKS
·
21 Feb

Glaukos Corp (GKOS) Q4 2024 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

GuruFocus.com
·
21 Feb

BUZZ-Glaukos rises after Mizuho upgrades rating to 'outperform'

Reuters
·
19 Feb